Houston, TX – June 30, 2021 – Pulmotect, Inc., a clinical-stage biotechnology company developing PUL-042, a novel, inhaled, innate immune-stimulating drug, today announced the appointment of William J. Noss III, CPA, as Chief Financial Officer.
“I am delighted to welcome Bill to Pulmotect at such an important time for the company,” said Dr. Colin Broom, CEO of Pulmotect. “His expertise and experience will help build our infrastructure as we continue the clinical development of PUL-042. It is an exciting time to join Pulmotect, with two Phase 2 clinical trials for the prevention and treatment of COVID-19 that have been supported with funding from the Department of Defense and our planned clinical trials for the prevention of respiratory complications in cancer patients.”
Mr. Noss joins Pulmotect with over 15 years of experience in the life science industry. Prior to Pulmotect, Mr. Noss was Executive Director / Controller for Harmony Biosciences, where he helped lead the company through their commercial launch and subsequently through their initial public offering of $148M. Before Harmony, he was Head of Finance at Aevi Genomic Medicine. Mr. Noss’s previous experience also includes various roles with Telerx, ViroPharma Incorporated, and KPMG LLP. Mr. Noss holds a Bachelor of Science in Accounting from King’s College, is a Chartered Global Management Accountant and a Certified Public Accountant.
“I am very excited to join this outstanding team as the company grows,” said Mr. Noss. “PUL-042 has the potential to protect patients from a broad range of viral and other pulmonary infections by activating the innate immune system. I look forward to playing a key role in the drug development program by working hard for the future benefit of patients and creating long-term value for the company and our stakeholders.”
Pulmotect is developing PUL-042, a clinical stage, first-in-class, inhaled immunomodulatory agent, which is a synergistic combination of two toll-like receptor agonists that amplifies the innate immune defenses of the lung epithelial mucosa to provide broad-spectrum, pathogen-agnostic protection against respiratory infections. Invented at UT MD Anderson Cancer Center/Texas A&M University, PUL-042 has patents issued in 10 countries, both as a stand-alone composition of matter product and in combination with antivirals. PUL-042 R&D has been supported by the National Institutes of Health (NIAID, NIGMS), the Cancer Prevention and Research Institute of Texas (CPRIT) and other funding agencies. The COVID-19 project is funded in part with federal funds from the DOD’s Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND), through the U.S. Army Contracting Command – New Jersey, under an Other Transaction Agreement (W15QKN-16-9-1002, Project #MCDC 2006-002) awarded to the Medical CBRN Defense Consortium and Pulmotect Inc.
For more information, visit www.pulmotect.com